rsp
20.01.2012, 23:57
Одно из самых ожидаемых исследований FAME II (по крайней мере для меня) среди пациентов со стабильной стенокардией возможно могут досрочно закрыть.
St. Jude Medical announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve-guided assessment was used to direct treatment in patients with coronary artery disease. As a result of the positive interim analysis, the FAME II independent Data Safety Monitoring Board has recommended investigators stop patient enrollment of this trial as the Data Safety Monitoring Board considers it unethical to continue to randomize patients to optimal medical therapy alone.
The Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease (FAME II) trial is a follow-up to the landmark FAME trial. The goal is to further study the role of fractional flow reserve (FFR) in the treatment of stable CAD by comparing percutaneous coronary intervention guided by FFR plus optimal medical therapy with optimal medical therapy alone.
подробностей пока не много FAME II clinical trial enrollment stopped after interim analysis showed benefit of FFR ([Ссылки могут видеть только зарегистрированные и активированные пользователи]).
Но, если это действительно произойдет, думаю, нынешний вес Куража в принятии клинических решений может существенно поубавиться.
St. Jude Medical announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when fractional flow reserve-guided assessment was used to direct treatment in patients with coronary artery disease. As a result of the positive interim analysis, the FAME II independent Data Safety Monitoring Board has recommended investigators stop patient enrollment of this trial as the Data Safety Monitoring Board considers it unethical to continue to randomize patients to optimal medical therapy alone.
The Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment vs. Optimal Medical Treatment Alone in Patients with Stable Coronary Artery Disease (FAME II) trial is a follow-up to the landmark FAME trial. The goal is to further study the role of fractional flow reserve (FFR) in the treatment of stable CAD by comparing percutaneous coronary intervention guided by FFR plus optimal medical therapy with optimal medical therapy alone.
подробностей пока не много FAME II clinical trial enrollment stopped after interim analysis showed benefit of FFR ([Ссылки могут видеть только зарегистрированные и активированные пользователи]).
Но, если это действительно произойдет, думаю, нынешний вес Куража в принятии клинических решений может существенно поубавиться.